Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAYNIER MOYA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1124288980
CMS profile
278302
Location
PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,741.44

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,741.44 2

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Chiesi USA, Inc. $1,741.44 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAYNIER MOYA

NPI 1124288980 · CMS profile ID 278302

Allopathic & Osteopathic Physicians / Internal Medicine

PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAYNIER MOYA, NPI 1124288980, CMS profile ID 278302. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JAYNIER MOYA, NPI 1124288980, CMS profile ID 278302. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JAYNIER MOYA, NPI 1124288980, CMS profile ID 278302, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $1,741.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Chiesi USA, Inc. $870.7201/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050859851 CMS
Chiesi USA, Inc. $870.7201/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051592383 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $128.50 2
PY2023 $1,741.44 2
PY2025 $15.30 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,567,242.14 108
PY2024 Recipient $1,161.49 6
PY2024 Principal investigator $5,059,140.87 296
PY2023 Recipient $2,506.25 1
PY2023 Principal investigator $14,127,127.37 743
PY2022 Recipient $24,618.00 1
PY2022 Principal investigator $15,001,316.81 131
PY2021 Principal investigator $6,255,399.36 48
PY2020 Principal investigator $653,923.11 62
PY2019 Principal investigator $748,551.83 218

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

62 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,977.51 12/31/2020 Non-covered Recipient Entity
Pines Care Research Center, Llc
A Phase 2b Multicenter Randomised Double blind Placebo controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricemia No dispute reported 06/30/2026 736747325
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,649.89 12/31/2020 Non-covered Recipient Entity
Pines Care Medical Center, Llc
A Phase 2b Multicenter Randomised Double blind Placebo controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricemia No dispute reported 06/30/2026 736750179
Principal investigator 1 PFIZER INC. $4,127.50 12/16/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742898839
Principal investigator 1 PFIZER INC. $9,080.50 12/03/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742898789
Principal investigator 1 PFIZER INC. $9,080.50 11/21/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742924457
Principal investigator 1 PFIZER INC. $6,604.00 10/29/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742924175
Principal investigator 1 PFIZER INC. $8,255.00 10/17/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742924461
Principal investigator 1 PFIZER INC. $8,255.00 10/01/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742924459
Principal investigator 1 PFIZER INC. $7,755.00 09/26/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A 12WEEK PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF06882961 TITRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH METFORMIN No dispute reported 06/30/2026 742924383
Principal investigator 1 PFIZER INC. $25,856.86 09/19/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742924025
Principal investigator 1 AstraZeneca Pharmaceuticals LP $50,240.10 09/14/2020 Non-covered Recipient Entity
Pines Care Research Center, Llc
A Phase 2b Multicenter Randomised Double blind Placebo controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricemia No dispute reported 06/30/2026 736735739
Principal investigator 1 PFIZER INC. $66,922.05 09/03/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742924027
Principal investigator 1 PFIZER INC. $3,521.70 09/03/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742924031
Principal investigator 1 PFIZER INC. $14,859.00 08/19/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742946675
Principal investigator 1 PFIZER INC. $16,510.00 08/01/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742946673
Principal investigator 1 PFIZER INC. $21,793.14 07/17/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742947009
Principal investigator 1 Ferring Pharmaceuticals AS $4,397.70 07/16/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 721460107
Principal investigator 1 AKEBIA THERAPEUTICS INC $19,227.95 07/13/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753285629
Principal investigator 1 PFIZER INC. $14,900.18 07/02/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742946575
Principal investigator 1 AKEBIA THERAPEUTICS INC $5,530.05 07/01/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753285233
Principal investigator 1 AKEBIA THERAPEUTICS INC $928.80 06/24/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753284899
Principal investigator 1 PFIZER INC. $110.88 06/23/2020 Non-covered Recipient Entity
Pines Care Medical Center
A 12WEEK PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF06882961 TITRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH METFORMIN No dispute reported 06/30/2026 742954013
Principal investigator 1 PFIZER INC. $89.36 06/23/2020 Non-covered Recipient Entity
Pines Care Medical Center
A 12WEEK PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF06882961 TITRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH METFORMIN No dispute reported 06/30/2026 742954017
Principal investigator 1 AKEBIA THERAPEUTICS INC $232.20 06/17/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753284795
Principal investigator 1 PFIZER INC. $26,490.76 06/16/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742947005
Principal investigator 1 AKEBIA THERAPEUTICS INC $745.20 06/09/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753284555
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,200.00 06/09/2020 Non-covered Recipient Entity
Pines Care Medical Center, Llc
A Phase 2b Multicenter Randomised Double blind Placebo controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricemia No dispute reported 06/30/2026 736741291
Principal investigator 1 PFIZER INC. $49,217.15 06/04/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742942213
Principal investigator 1 Ferring Pharmaceuticals AS $360.90 06/01/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 721459925
Principal investigator 1 PFIZER INC. $19,475.96 05/29/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742964987
Principal investigator 1 PFIZER INC. $7,755.00 05/15/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A 12WEEK PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF06882961 TITRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH METFORMIN No dispute reported 06/30/2026 742960009
Principal investigator 1 PFIZER INC. $41,457.94 05/15/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742964989
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,339.10 05/11/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753283683
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,410.30 05/06/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753283541
Principal investigator 1 PFIZER INC. $15,157.60 05/02/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742964921
Principal investigator 1 PFIZER INC. $11,121.16 04/30/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742964991
Principal investigator 1 PFIZER INC. $25,107.58 04/21/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742964711
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,719.00 04/01/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753282433
Principal investigator 1 AKEBIA THERAPEUTICS INC $5,368.50 04/01/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753282731
Principal investigator 1 PFIZER INC. $13,103.30 03/19/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742964707
Principal investigator 1 AKEBIA THERAPEUTICS INC $5,517.90 03/16/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753282053
Principal investigator 1 PFIZER INC. $676.89 03/12/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742964917
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,437.20 03/02/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753281709
Principal investigator 1 Ferring Pharmaceuticals AS $2,500.00 03/02/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 721459671
Principal investigator 1 PFIZER INC. $2,537.92 02/28/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742970583
Principal investigator 1 AKEBIA THERAPEUTICS INC $773.10 02/25/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753289339
Principal investigator 1 AKEBIA THERAPEUTICS INC $5,360.40 02/24/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753289125
Principal investigator 1 PFIZER INC. $13,029.26 02/21/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742970541
Principal investigator 1 PFIZER INC. $2,030.67 02/19/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742970469
Principal investigator 1 PFIZER INC. $676.89 02/19/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742970539
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,680.30 02/13/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753288961
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,641.60 02/10/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753288687
Principal investigator 1 PFIZER INC. $451.26 02/06/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742970537
Principal investigator 1 AKEBIA THERAPEUTICS INC $10,034.10 02/05/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753288459
Principal investigator 1 PFIZER INC. $11,578.13 02/01/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742970579
Principal investigator 1 PFIZER INC. $8,663.53 01/22/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742970519
Principal investigator 1 PFIZER INC. $1,353.78 01/22/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742970817
Principal investigator 1 PFIZER INC. $451.26 01/17/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742970889
Principal investigator 1 Ferring Pharmaceuticals AS $370.80 01/09/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 721459539
Principal investigator 1 PFIZER INC. $28,145.80 01/08/2020 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742970471
Principal investigator 1 AKEBIA THERAPEUTICS INC $773.10 01/02/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753287611
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,304.90 01/02/2020 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753287715